Three-arm randomized phase II study evaluating oral vinorelbine plus capecitabine versus paclitaxel plus gemcitabine versus docetaxel plus gemcitabine as first-line chemotherapy in patients with metastatic breast cancer: Final results (NorCap-CA223 trial).
Saverio Cinieri(Ospedale A. Perrino), Uğur Çoşkun, María José Godes(Hospital General Universitario De Valencia), Jesús Cárdenas(Universidad de Colima), Р. Ш. Хасанов, Agustí Barnadas, C. Slabber(Life Groenkloof Hospital), Silvia Lazzarelli(Istituti Ospitalieri di Cremona), Patricia Dodyk, Dar‐Ren Chen(Changhua Christian Hospital), Marcus Schmidt(Johannes Gutenberg University Mainz), Javier Castellanos Diez, G. Villanova(Pierre Fabre (France)), Philippe Bougnoux(Centre Hospitalier Universitaire de Tours), N. Tubiana-Mathieu(Centre Hospitalier Universitaire de Limoges), Ann Vandebroek(ZNA Middelheim Hospital), Kadri Altundağ(Hacettepe University Hospital), Arlene Chan(Curtin University), Michiel Botha, Daniel Rauch(Washington University in St. Louis)
Cited by 3
Related Papers
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
|The Lancet|2011|1.1k
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
|Journal of Clinical Oncology|2010|887
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|594